Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization (WHO) for children at risk of severe malaria in areas with highly seasonal transmission. Ensuring effective reporting and management of adverse events (AEs) is crucial for ensuring safety and sustaining the acceptability of SMC. This study assessed the frequency of AEs following administration of sulfadoxine-pyrimethamine and amodiaquine (SPAQ) for SMC, caregiver knowledge of AEs and the frequency of reporting of AEs in Karamoja region, Uganda.
This poster was presented at the Multilateral Initiative on Malaria (MIM) Society's 8th Pan-African Malaria Conference.
« Back to Publications